The Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Fixed Combination Ophthalmic Solution
Authors:
- Howard S. BarnebeyHBHoward S. Barnebey
- Silvia Orengo-NaniaSOSilvia Orengo-Nania
- Brian E. FlowersBFBrian E. Flowers
- John SamplesJSJohn Samples
- Sushanta MallickSMSushanta Mallick
- Theresa A. LandryTLTheresa A. Landry
- Michael V.W. BergaminiMBMichael V.W. Bergamini
- 1 July 2005
- journal article
- clinical trial
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 140 (1) , 1.e1-1.e8
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Human Ciliary Muscle Cell Responses to FP-Class Prostaglandin Analogs: Phosphoinositide Hydrolysis, Intracellular Ca 2+ Mobilization and MAP Kinase ActivationJournal of Ocular Pharmacology and Therapeutics, 2003
- Human Trabecular Meshwork Cell Responses Induced by Bimatoprost, Travoprost, Unoprostone, and other FP Prostaglandin Receptor Agonist AnaloguesInvestigative Ophthalmology & Visual Science, 2003
- The Ocular Hypertension Treatment StudyArchives of Ophthalmology (1950), 2002
- Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressureOphthalmology, 2002
- Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertensionAmerican Journal of Ophthalmology, 2001
- Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamicsAmerican Journal of Ophthalmology, 2001
- The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deteriorationAmerican Journal of Ophthalmology, 2000
- The Mechanism of Betaxolol, a New Ocular Hypotensive AgentOphthalmology, 1983
- TimololOphthalmology, 1981
- TimololArchives of Ophthalmology (1950), 1977